Treatment of chronic mucocutaneous candidiasis with 5-fluorocytosine.
A four-year-old girl with chronic mucocutaneous candidiasis (CMC) and an immunologic deficiency syndrome was studied in detail over a period of two years. Her lymphocytes neither produced migratory inhibitory factor nor responded consistently with an increased 3H-thymidine uptake when placed in tissue culture medium with candida antigen. The serum IgE was increased. No autoantibody was demonstrated in the patient's serum and she did not have nay kind of endocrine disorder. Eradication of the candida infection with 5-fluorocytosine, although resulting in marked clinical improvement, did not alter the immunologic abnormalities.
D000917:Antibody Formation; D002177:Candidiasis / Q000188:drug therapy*; D002178:Candidiasis, Chronic Mucocutaneous / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D002675:Child, Preschool; D003596:Cytosine / Q000031:analogs & derivatives*; D005260:Female; D005437:Flucytosine / Q000627:therapeutic use*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000175:diagnosis; D007073:Immunoglobulin E / Q000096:biosynthesis; D008213:Lymphocyte Activation; D008263:Macrophage Migration-Inhibitory Factors / Q000096:biosynthesis; D012882:Skin Tests; D013601:T-Lymphocytes / Q000145:classification; D013624:Taiwan
D008263:Macrophage Migration-Inhibitory Factors; D007073:Immunoglobulin E; D003596:Cytosine; D005437:Flucytosine